Improved Prescription Fulfillment And Primary Care Entry Will Unlock Opportunity

Published
10 Apr 25
Updated
20 May 25
AnalystConsensusTarget's Fair Value
US$18.22
47.3% undervalued intrinsic discount
20 May
US$9.60
Loading
1Y
-44.8%
7D
1.6%

Author's Valuation

US$18.2

47.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 1.22%

AnalystConsensusTarget has increased profit margin from 0.6% to 19.8%, decreased future PE multiple from 231.3x to 9.8x and increased shares outstanding growth rate from 0.0% to 0.1%.